April 21 - The caprolactam-to-hexamethylenediamine (HMDA) unit independently developed by China Xuyang has recently completed catalyst loading, laying the foundation for its commissioning in April. The unit is expected to achieve an annual production capacity of approximately 30,000 tons by 2026.

Chempricehub Analysis:

• Caprolactam: Bullish/Bearish Score: 1
  China Xuyang's new unit uses caprolactam as a raw material to produce HMDA. The expected production of 30,000 tons in 2026 will increase the demand for caprolactam, leading to higher consumption of this key raw material. This is expected to support a rise in spot prices. Additionally, reduced supply-side pressure may drive short-term price increases.

• Hexamethylenediamine (HMDA): Bullish/Bearish Score: -1
  The commissioning of the new unit will add approximately 30,000 tons of HMDA supply, significantly boosting market availability. This may lead to an imbalance between supply and demand, putting downward pressure on spot prices. The expansion of production capacity will intensify competitive pressures, limiting the potential for price rebounds.